COR Therapeutics, Inc. (extinct)

COR Therapeutics, Inc. (extinct)

COR Therapeutics, Inc. (extinct)

Date Founded



256 East Grand Avenue,Suite 80,South San Francisco, CA 94080

Type of Company




Company Description

COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction

Contact Data
Trying to get in touch with decision makers at COR Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Product Director

Paths to COR Therapeutics, Inc.
Potential Connections via
Relationship Science
COR Therapeutics, Inc.
Transaction Advisors
Legal Advisor

Advised onTakeda Oncology Co. purchases COR Therapeutics, Inc.


Advised onTakeda Oncology Co. purchases COR Therapeutics, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by COR Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of COR Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and COR Therapeutics, Inc..